Back to Search

ATHANASSIOS ARGIRIS, MD

MD

Hematology & Oncology Physician

NPI: 1174608509Individual

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

MD425927(PA)P0338(TX)

Research & Publications (20)

Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers.
PMID 19602566·Ann Oncol·2010
8-other
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
PMID 19464819·Int J Radiat Oncol Biol Phys·2009
3-trial
Targeting angiogenesis from premalignancy to metastases.
PMID 19336719·Cancer Prev Res (Phila)·2009
6-review
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
PMID 19634157·Cancer·2009
3-trial
Cetuximab-induced aseptic meningitis.
PMID 19643807·Ann Oncol·2009
5-case
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
PMID 19204206·J Clin Oncol·2009
3-trial
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
PMID 18683883·Cancer·2008
8-other
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer.
PMID 18091334·Laryngoscope·2008
3-trial
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
PMID 18296423·Ann Oncol·2008
3-trial
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
PMID 18381949·Clin Cancer Res·2008
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
7979 WURZBACH RD
SAN ANTONIO, TX 78229

Quick Facts

NPI
1174608509
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile